Boucher CA - Search Results

1

Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.

Boucher CA, van Leeuwen R, Kellam P, Schipper P, Tijnagel J, Lange JM, Larder BA. Boucher CA, et al. Antimicrob Agents Chemother. 1993 Jul;37(7):1525-30. doi: 10.1128/AAC.37.7.1525. Antimicrob Agents Chemother. 1993. PMID: 8103317 Free PMC article.

2

HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Boucher CA, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, Tersmette M. Boucher CA, et al. AIDS. 1992 Nov;6(11):1259-64. doi: 10.1097/00002030-199211000-00003. AIDS. 1992. PMID: 1282015

3

HIV-1 sensitivity to zidovudine and clinical outcome.

Boucher CA, Lange JM. Boucher CA, et al. Lancet. 1992 Mar 7;339(8793):626. Lancet. 1992. PMID: 1347137 No abstract available.

4

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA. Boucher CA, et al. J Infect Dis. 1992 Jan;165(1):105-10. doi: 10.1093/infdis/165.1.105. J Infect Dis. 1992. PMID: 1370174

5

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Kellam P, Boucher CA, Larder BA. Kellam P, et al. Among authors: boucher ca. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934-8. doi: 10.1073/pnas.89.5.1934. Proc Natl Acad Sci U S A. 1992. PMID: 1371886 Free PMC article.

6

Clinical significance of zidovudine-resistant human immunodeficiency viruses.

Boucher CA. Boucher CA. Res Virol. 1992 Mar-Apr;143(2):134-6. doi: 10.1016/s0923-2516(06)80098-1. Res Virol. 1992. PMID: 1594797 Review. No abstract available.

7

Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.

Reiss P, de Wolf F, Kuiken CL, de Ronde A, Dekker J, Boucher CA, Debouck C, Lange JM, Goudsmit J. Reiss P, et al. Among authors: boucher ca. J Acquir Immune Defic Syndr (1988). 1991;4(2):165-72. J Acquir Immune Defic Syndr (1988). 1991. PMID: 1898969

8

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

Boucher CA, Tersmette M, Lange JM, Kellam P, de Goede RE, Mulder JW, Darby G, Goudsmit J, Larder BA. Boucher CA, et al. Lancet. 1990 Sep 8;336(8715):585-90. doi: 10.1016/0140-6736(90)93391-2. Lancet. 1990. PMID: 1975378

9

Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

Lange JM, Boucher CA, Hollak CE, Wiltink EH, Reiss P, van Royen EA, Roos M, Danner SA, Goudsmit J. Lange JM, et al. Among authors: boucher ca. N Engl J Med. 1990 May 10;322(19):1375-7. doi: 10.1056/NEJM199005103221907. N Engl J Med. 1990. PMID: 2325735 Free article. No abstract available.

10

Resumption of HIV antigen production during continuous zidovudine treatment.

Reiss P, Lange JM, Boucher CA, Danner SA, Goudsmit J. Reiss P, et al. Among authors: boucher ca. Lancet. 1988 Feb 20;1(8582):421. doi: 10.1016/s0140-6736(88)91219-6. Lancet. 1988. PMID: 2893226 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

505 results

Search Page

Filters